


MYCENAX

Cell Line

Development

Services



NaxLEAP™

Proprietary Technology

Improve genomic
integration



Beacon®

Optofluidic System

Rapidly identify high-yield
single-cell clones &
provide compliant, image-
based clonality evidence



Vector Design

Optimize gene
orientation &
expression efficiency



**Host Cell
Selection**

Ensures
stability &
productivity

MYCENAX BIOTECH INC.

20+ years of expertise in process development & cGMP manufacturing for biologics and biosimilars, including specialized modalities, ADCs, pDNA, and cell & gene therapy.

- Global Regulatory Compliance: EMA, PMDA, Health Canada, etc.
- 2 GMP Plants: Drug Substance & Drug Product services.

CONNECT WITH US



+886-3-667-0880



info@mycenax.com





www.mycenax.com



NaxLEAP™ Proprietary Technology

Application of NaxLEAP™ system significantly improved cell pool productivity and stability, enabling early protein production for development and preclinical studies, leading to a faster development timeline.



Beacon® Optofluidic System



By leveraging Beacon Optofluidic System, cell line development timelines can be shortened by up to **1.5 months**—bringing your biologics to market faster.

RapidMab™ From DNA to RCB in 4.5 months

Mycenax's RapidMab™ platform combines solid expertise with advanced technology to initiate your project from an early stage. Our Cell Line Development platform consistently delivers well-characterized, stable single-cell clones—from DNA to Research Cell Bank (RCB)—within 4.5 months.